β-Amyloid Deposition Monitoring and Control Systems for Industrial and Agricultural Applications

Publication ID: 24-11857568_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “β-Amyloid Deposition Monitoring and Control Systems for Industrial and Agricultural Applications,” Published Technical Disclosure No. 24-11857568_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857568_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,568.

Summary of the Inventive Concept

The present inventive concept relates to novel systems and methods for monitoring and controlling β-amyloid deposition in various industries, leveraging the core technology of the original patent to address unmet needs in water quality, biofilm formation, agricultural soil health, and air quality.

Background and Problem Solved

The original patent disclosed means and methods for treating and preventing Alzheimer's disease, focusing on the role of β-amyloid deposition in dementia. However, β-amyloid deposition is not exclusive to biological systems and can have significant implications in industrial and agricultural contexts. The present inventive concept addresses the limitations of the original patent by applying its core technology to entirely new fields, providing innovative solutions for monitoring and controlling β-amyloid deposition in these industries.

Detailed Description of the Inventive Concept

The newly generated claims describe systems and methods for detecting β-amyloid deposition in water samples, industrial equipment, agricultural soil, and air samples. These systems comprise sensors for detecting β-amyloid deposition and controllers for adjusting treatment parameters or implementing corrective actions. The inventive concept also encompasses methods for reducing biofilm formation, improving crop yields, and enhancing air quality by administering aluminum salts to inhibit β-amyloid deposition. The systems and methods can be integrated into existing industrial and agricultural processes, providing a proactive approach to mitigating the effects of β-amyloid deposition.

Novelty and Inventive Step

The novelty of the present inventive concept lies in its application of β-amyloid deposition monitoring and control to industrial and agricultural contexts, which was not contemplated in the original patent. The inventive step resides in the recognition of the relevance of β-amyloid deposition to these fields and the development of tailored systems and methods to address the specific challenges posed by β-amyloid deposition in these industries.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different sensors or detection methods, variations in the aluminum salt administration protocols, or the integration of machine learning algorithms to optimize system performance. Additionally, the inventive concept could be adapted for use in other industries, such as cosmetics or pharmaceuticals, where β-amyloid deposition may have significant implications.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in various industries, including water treatment, industrial equipment manufacturing, agriculture, and air quality management. The market for β-amyloid deposition monitoring and control systems is expected to grow rapidly as industries recognize the importance of addressing this previously overlooked issue. Advantage Therapeutics, Inc. is well-positioned to capitalize on this opportunity, leveraging its expertise in β-amyloid deposition to develop innovative solutions for a broad range of industrial and agricultural applications.

Original Patent Information

Patent NumberUS 11,857,568
TitleTreatment and prevention of Alzheimer's disease (AD)
Assignee(s)Advantage Therapeutics, Inc.